On the other hand, European NSCLC guidelines recommend NGS‐based genomic testing for EGFR, ALK, ROS1, BRAF NTRK, and KRAS, while in Spain, guidelines recommend molecular testing of EGFR, ALK, ROS1, and BRAF, but only suggest additional testing of genes such as KRAS and NTRK if previous biomarker testing yields negative results, we reflect in our study.12 This evidence concerns the gene KRAS and non-small cell lung carcinoma.